Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 155

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 155
---
b Co.), Actinium Pharmaceuticals,
Inc., RadioMedix, Inc., Orano SA and Telix Pharmaceuticals Limited. These companies are targeting a wide range of solid and hematologic
malignancies using various alpha emitting isotopes, including Radium-223, Actinium-225, Lead-212 and Thorium-227. The first and only approved
alpha particle-based therapy is Bayer’s Xofigo, a salt of Radium-223 that cannot easily and robustly be attached to a targeting
molecule, but naturally localizes to regions where cancer cells are infiltrating bone. Xofigo was approved in 2013 for the treatment of
bone metastases associated with prostate cancer.

Many of our current or potential
competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research
and development, manufacturing, pre-clinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved
products than we do. Mergers and acquisitions in the pharmaceutical, medical device and biotechnology industries may result in even more
resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant
competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with
us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient enrollment
in clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

We could see a reduction or
elimination in our commercial opportunity if our competitors develop and commercialize treatments that are safer, more effective, have
fewer or less severe side effects, are more convenient to administer, are less expensive or have a more favorable label than our Alpha
DaRT technology. Our competitors also may obtain FDA or other regulatory approval for their treatments more rapidly than we may obtain
approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.
The key competitive factors affecting the success of all of our product candidates, if approved, are likely to be their efficacy, safety,
convenience and ease of use, price, the effectiveness of imaging diagnostics, the level of generic competition and the availability of
reimbursement from government and other third-party payors.

Seasonality

Our business historically
has not been subject to seasonal variations.

Our Intellectual Property

As of December 31, 2024, our
patent portfolio included 151 issued patents, and